Welcome
This section of the website provides the financial market, owners and other interested parties with information about our business and performance.
Some information may be provided in Swedish only.
Introduction
Qlucore develops AI‑based software that enables more accurate diagnostics and a more cost‑efficient healthcare system. Through the company’s precision medicine solutions, tens of thousands of genetic data points are transformed into clear decision‑making support, making it possible to deliver the right treatment to each patient at the right time.
The first diagnostic test – for pediatric blood cancer – has been approved for sale within the EU. Additional tests, including for lung cancer, adult blood cancer, and bladder cancer, are under development. These products target large and growing markets with significant medical and economic needs. The goal is to improve treatment outcomes, reduce human suffering, and lower healthcare costs.
In addition to its diagnostics portfolio, Qlucore offers Qlucore Omics Explorer, an established software platform for advanced data analysis used by researchers and pharmaceutical companies worldwide. The company has customers in 20 countries, sales offices in Europe and North America, and distributors across several Asian markets.